Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
PLN 24.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome....
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of RVU.WA is 39 and suggests 58% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Data is available to registered users only
Buy
Sell